Lyfegen Accelerates AI Contracting Push and Scaling Efforts With New Tool and Talent Hires

Lyfegen, a healthtech company focused on drug pricing and market access, used the past week to advance its AI-driven contracting strategy and scale-up preparations. The firm unveiled its AI Contracting Companion at the World Evidence, Pricing and Access Congress in Amsterdam, positioning the tool as a generative AI assistant for pharmaceutical pricing and access teams.

The AI Contracting Companion is designed to translate evidence, payer insights, and pricing scenarios into real-time contracting strategies. Lyfegen aims to help pharma clients manage rising pricing interdependencies, complex rebate structures, and pressures from policies such as most-favored-nation rules and cross-market spillovers.

Through the launch, Lyfegen is targeting budget holders and market access teams seeking to accelerate patient access and modernize contract workflows. The company emphasizes that payer access is increasingly determined by contract structures rather than headline launch prices, reinforcing the strategic role of advanced contracting tools.

Lyfegen also highlighted a broader AI-enabled, conversational framework for preparing market access contracts, moving away from static checklists and manual preparation. This approach is intended to allow users to test trade-offs, anticipate payer expectations, and generate more defensible, data-driven contracting strategies across multiple markets.

Complementing the product launch, Lyfegen published a trends report titled “Staying Ahead of the MFN Curveball,” examining how U.S. Most Favored Nation models may be reshaping pricing across 19 reference markets. The firm argues that global launch strategies are becoming increasingly interdependent, raising execution and compliance risks for manufacturers.

To reinforce its analytical capabilities, Lyfegen hired Elliot Taylor as Senior Market Access and Pricing Analyst to focus on pricing agreements, reimbursement models, and policy trends. In parallel, the company expanded its talent acquisition capacity by adding two Senior Talent Recruiters, signaling anticipated headcount growth and organizational scaling.

The build-out of an internal recruitment function suggests Lyfegen is preparing for a broader hiring push across product, commercial, and operational roles. A more structured, full-cycle recruitment approach may help the firm secure specialized healthtech talent and support smoother scale-up execution.

Taken together, Lyfegen’s AI product launch, thought leadership on MFN pricing dynamics, and investments in both analytical and recruitment talent point to a concerted effort to deepen its role in market access technology. These moves could enhance the company’s competitive positioning and recurring revenue potential as pharma and payers adopt more complex, AI-enabled contracting solutions.